Rates of combination antiretroviral treatment change in Australia, 1997–2000
- 1 January 2002
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 3 (1) , 28-36
- https://doi.org/10.1046/j.1464-2662.2001.00094.x
Abstract
Objective To estimate the rate of combination antiretroviral treatment change and factors associated with combination antiretroviral treatment change among patients recruited in the Australian HIV Observational Database (AHOD). Methods Analyses were based on patients in the AHOD who had commenced combination antiretroviral treatment after 1 January 1997. Combination antiretroviral treatment change was defined as the addition or change of at least one antiretroviral drug. A random-effect Poisson regression model was used to assess factors associated with increased rates of combination antiretroviral treatment change. Results A total of 596 patients in the AHOD were included in the analysis, with a median follow-up of 2.3 years. The overall rate of antiretroviral treatment change in this group was 0.45 combinations per year. In a multivariate analysis, a low CD4 count (< 200 cells/μL) at baseline was associated with an increased rate of treatment change [rate ratio (RR)=1.43; 95% confidence interval (CI), 1.13, 1.80; P=0.003)]. Combinations including a nonnucleoside reverse transcriptase inhibitor were also associated with slower rates of change than treatment combinations including a protease inhibitor (RR=0.64, 95% CI, 0.51, 0.80, P < 0.001). Conclusion Initiating combination antiretroviral at a CD4 cell count < 200 cells/μL may be associated with poorer patient outcomes. However, the possibility that clinician or patient concerns about low immunological status led to faster rates of treatment change in this group cannot be discounted.Keywords
This publication has 10 references indexed in Scilit:
- The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral loadAIDS, 2001
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patientsAIDS, 2000
- Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitorAIDS, 2000
- Estimating the population impact in Australia of improved antiretroviral treatment for HIV infectionAIDS, 2000
- CD4 cell counts at the third month of HAART may predict clinical failureAIDS, 1999
- Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA StudyAnnals of Internal Medicine, 1999
- HIV disease progression in Australia in the time of combination antiretroviral therapiesThe Medical Journal of Australia, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Some approaches to the analysis of recurrent event dataStatistical Methods in Medical Research, 1994